RPG Life Sciences Reports Strong Q1 FY27 Results; Revenue Rises 15.8% as EBITDA Margin Expands

RPG Life Sciences Reports Strong Q1 FY27 Results; Revenue Rises 15.8% as EBITDA Margin Expands​

RPG Life Sciences Limited announced its financial results for the quarter ended June 30, 2026, reporting robust growth and improved profitability across its various segments. The company noted that its domestic formulations business outperformed the broader Indian pharmaceutical market, contributing to its recognition within the Top 50 Indian pharma companies list in June 2026.

The company commenced FY27 with significant gains, driven by disciplined operations and strategic initiatives. Revenue from Operations increased 15.8% year-on-year (YoY), while EBITDA grew 17.9%. The improved operating efficiency was reflected in the EBITDA margin, which rose by 40 basis points (bps).

Financial Performance Snapshot​

The following table provides a detailed look at the financial indicators for Q1 FY27 compared to Q1 FY26:

Operational Highlights and Business Segments​

The Domestic Formulations business remained a key growth driver, recording 14.8% growth during the quarter, surpassing the Indian Pharma Market’s expansion rate of 11.6%. This success is attributed to strategic launches, enhanced field-force effectiveness, and a sustained focus on key therapies.

In parallel, International Formulations saw 7.7% growth in the quarter. The API business achieved substantial growth at 35.6%, following the successful restoration of units back into operations.

Commenting on the results, Mr. Ashok Nair, Managing Director of RPG Life Sciences Ltd., stated that the company started FY27 strongly, continuing its trend of market-beating performance. He noted that the domestic segment’s outperformance was instrumental in enabling the company to secure a spot in the Top 50 ranking within the Indian Pharma Market.

Mr. Nair further elaborated on future strategies, emphasizing the commitment to strengthening international presence through customer onboarding and market expansion. He also highlighted plans to scale up API operations as a primary driver for long-term growth, expressing confidence in sustaining momentum backed by strong profitability and continued talent investment.

Key Achievements and Recognitions​

RPG Life Sciences achieved several operational milestones during the quarter:

• The Naprosyn product line registered 16% growth this quarter, alongside double-digit growth observed across key therapeutic areas such as nephrology and rheumatology.
• The company received recognition as 'Top Nephrology Company' for 2026 from India Pharma Outlook.
• RPG Life Sciences was recognized by Bluetech Media for ‘Best Use of AI in Sales Force Effectiveness.’
• It also secured the award for ‘Excellence in Breakthrough Pharmaceutical Innovations’ from Network 7 Media, based on the Pharmarack MAT June 2026 Database.

As an integrated research-based pharmaceutical company, RPG Life Sciences operates across both domestic and international markets in branded formulations, global generics, and synthetic APIs, offering a wide range of trusted and affordable medicines.

RPGLIFE Stock Price Movement​

Shares of RPG Life Sciences Limited settled at ₹2888.70 after shedding 1.81% in post-market trading today. The stock saw action ranging between a high of ₹2924.60 and a low of ₹2850, with 8,327 shares traded during the session.